top of page
ADELA
ELACESTRANT + EVEROLIMUS IN PATIENTS WITH ER+/HER2-, ESR1MUT, ADVANCED BREAST CANCER PROGRESSING ON ENDOCRINE THERAPY AND CDK4/6 INHIBITORS
CLINICAL TRIAL DETAILS
A RANDOMIZED PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ELACESTRANT PLUS EVEROLIMUS VERSUS ELACESTRANT IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE, ESR1-MUTATED, ADVANCED BREAST CANCER PROGRESSING TO ENDOCRINE THERAPY AND CDK4/6 INHIBITORS
ADELA AT CLINICALTRIALS.GOV
ER+/HER2-
ABC
III
240
110
Austria, Brazil, Czech Republic, Spain, France, Greece, Italy, Germany and UK
Recruiting
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
bottom of page